Viridian Therapeutics, Inc.
VRDN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001590750
In the last 90 days, Viridian Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 214 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Viridian Therapeutics, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 132 | 136 | +4 |
| Shares | 60.1M | 71.0M | +10.9M (+18.1%) |
| Value | $1.31B | $1.24B | −$66.1M (−5.0%) |
New holders (23)
Institutions that held Viridian Therapeutics, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
Sold out (19)
Institutions that held Viridian Therapeutics, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Vestal Point Capital, LP | 1,000,000 | $21.8M |
| Jefferies Financial Group Inc. | 540,669 | $11.8M |
| Braidwell LP | 323,102 | $7.04M |
| Weiss Multi-Strategy Advisers LLC | 125,000 | $2.72M |
| Ensign Peak Advisors, Inc | 89,185 | $1.94M |
| ExodusPoint Capital Management, LP | 58,903 | $1.28M |
| Silverarc Capital Management, LLC | 50,438 | $1.10M |
| Affinity Asset Advisors, LLC | 50,000 | $1.09M |
| Balyasny Asset Management LLC | 41,214 | $897.6K |
| SG Americas Securities, LLC | 40,588 | $884.0K |
| Atika Capital Management LLC | 39,000 | $849.4K |
| Hudson Bay Capital Management LP | 35,176 | $766.1K |
| Tudor Investment Corp Et Al | 30,218 | $658.1K |
| Virtu Financial LLC | 19,456 | $424.0K |
| Natixis | 19,317 | $420.7K |
| Walleye Trading LLC | 16,602 | $361.6K |
| LMR Partners LLP | 10,000 | $217.8K |
| Simplex Trading, LLC | 2,856 | $62.0K |
| Group One Trading, L.P. | 17 | $370 |